Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...
The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01% ...
MarketBeat on MSN
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken ...
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback